Source: news.com.au, November 2018 BRISBANE mum Alyshia Morris was shaken to the core when she was diagnosed with two melanomas at the age of 32. She’s turned her negative experience into a positive, coming up with a way to not only stay sun smart herself, but encourage others to do the same. BRISBANE mother Alyshia […]
Posted in Melanoma News, Patients, Patient Stories
Source: OncLive, November 2018 Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation. The first 6 patients treated with either of 2 doses of engineered T-cells targeting melanoma-associated antigen-A4 (MAGE-A4) had a variety of adverse events (AEs), but treatment-related grade ?3 AEs […]
Posted in Melanoma News, Health Professionals, Of Interest
Source: Evaluate, November 2018 Oncology projects that disrupt the tumour microenvironment are hot property, and – after Aduro’s $225m deal with Novartis and Bristol-Myers Squibb’s $300m takeover of IFM Therapeutics – the Sting pathway is seen as particularly attractive. This is why the first clinical data with Merck & Co’s Sting agonist MK-1454, presented at […]
Posted in Melanoma News, Health Professionals, Clinical Trials
Source: Ecancer, November 2018 Prof Paolo Ascierto speaks with ecancer at ESMO 2018 in Munich about results from a phase 2 randomised study of dabrafenib and trametinib plus PD-L1 checkpoint therapy pembrolizumab for BRAFm advanced melanoma. Prof Ascierto discusses how immuno-oncology is adding to melanoma treatment, with the dabrafenib trametinib combination already found effective in the adjuvant […]
Posted in Melanoma News, Health Professionals, Clinical Trials
